Cybin Initiates Phase 3 Study for Psychedelic Drug CYB003

Thursday, 14 March 2024, 16:52

Cybin (CYBN) is set to kick off a Phase 3 clinical trial for its psychedelic treatment CYB003 targeting major depressive disorder. The company's move highlights the advancing research and development in the field of psychedelic therapy, aiming to address mental health challenges with innovative solutions. The Phase 3 program signifies a critical step towards potential new treatment options for individuals battling major depressive disorder.

https://store.livarava.com/4efff394-e224-11ee-9671-5254a2021b2b.jpe — Cybin Initiates Phase 3 Study for Psychedelic Drug CYB003

Cybin to begin Phase 3 study for psychedelic drug mid-year

Cybin (CYBN) announced its intention to commence a Phase 3 program in mid-year for its psychedelic-based therapy CYB003, aimed at treating major depressive disorder.

Key Points:

Cybin (CYBN) planning to start Phase 3 study for CYB003 mid-year
Focus on major depressive disorder treatment
Advancements in psychedelic therapy research and development

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Cybin to begin Phase 3 study for psychedelic drug mid-year

Key Points:

Related posts